Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend i

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05%

GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer,

FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expandin

U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembr

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA)

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted ma

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) acc

This donation, along with the additional supply being readied, continues the company's long-stan

Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda

– Novel Investigational Combination Pairs Merck's Islatravir, a Next-Generation Nucleoside Analo

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (N

Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed

Gilead applauds the leadership of the Government of South Africa and the Global Fund for acceleratin

Gilead reports positive Phase 3 Livdelzi data in PBC, with more patients achieving ALP normalization

CONSHOHOCKEN, Pa. [June 2, 2026] — Cencora today announced an agreement with Kite , a Gilead Company

Gilead Sciences, Inc. (NASDAQ:GILD) today announced positive results from a Phase 3 study in people